ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BGC Bristol Gate Concentrated Canadian Equity ETF

31.19
0.33 (1.07%)
31 May 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Bristol Gate Concentrated Canadian Equity ETF TSX:BGC Toronto Exchange Traded Fund
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.33 1.07% 31.19 31.13 31.46 0 22:00:00

BacTech Announces Financing

18/02/2010 12:02pm

Marketwired Canada


BacTech Mining Corporation ("BacTech" or the "Company") (TSX VENTURE:BM) today
announced that it proposes to complete a financing transaction to raise
$750,000. BacTech has received strong expressions of interest from investors for
the full amount of the financing.


The financing is being carried out in anticipation of the corporate
reorganization of BacTech described in the press release dated January 12, 2010
(the "Reorganization"). Pursuant to the Reorganization, BacTech will transfer to
its wholly-owned subsidiary, BacTech Gold Corporation ("BGC") all of BacTech's
interests in mineral exploration properties, together with the rights to
BacTech's proprietary bioleaching processes as they apply to primary mineral
processing. BacTech will then distribute to its shareholders common shares of
BGC ("BGC Shares"), on the basis of one BGC Share for each three BacTech shares.
Based on the number of common shares of BacTech currently outstanding,
approximately 30 million BGC Shares would be distributed. The Reorganization is
subject to approval by the shareholders of BacTech and the TSX Venture Exchange,
and there is no assurance that the Reorganization will be completed.


Pursuant to the financing transaction, BacTech will issue 750 Subscription
Receipts at a price of $1,000 each, to raise gross proceeds of $750,000. Upon
completion of the Reorganization, the Subscription Receipts will be
automatically exchanged for that number of BGC Shares which will represent 22.5%
of the outstanding BGC Shares immediately after the transaction (which number is
expected to be approximately 8.7 million BGC Shares), together with 7.5 million
warrants of BGC (the "BGC Warrants"). Each BGC Warrant will be exercisable for
one BGC Share at a price of $0.10 per share for 18 months. BacTech will also pay
to the holders of the Subscription Receipts interest at the rate of 10% per
annum for the period from the date of closing of the Subscription Receipt
financing to the effective date of the Reorganization. In the event the
Reorganization is not completed within six months, BacTech will be obligated to
repay the subscription price for the Subscription Receipts, together with
interest at the rate of 10% per annum, and issue to the holders an aggregate of
6,000,000 BacTech warrants exercisable at $0.10 per share for 18 months.


In connection with the Subscription Receipt financing, and subject to approval
by the Exchange, a finder's fee of 5% cash may be paid to certain arm's length
parties. Insiders of BacTech may subscribe for up to $100,000 of the financing.


Proceeds will be used to fund ongoing test work that BacTech has underway on
various projects such as the Lichkvaz-Tey gold deposit in Armenia and a project
under evaluation in Guatemala, together with the costs associated with the
Reorganization.


BACTECH PROFILE

BacTech owns patented bacterial oxidation technology for the treatment of
refractory ores and concentrates to enhance the recovery of gold, silver and
base metals. The Company's focus is the acquisition of equity positions in
projects amenable to bioleaching. In January the Company announced its intention
to effect a divisive reorganization whereby BacTech will transfer all of its
interests in mining projects and the rights to its bioleaching technology to a
wholly-owned subsidiary. The common shares of the subsidiary will be distributed
to the shareholders of BacTech upon completion of the reorganization. BacTech
will hold an exclusive and perpetual right to use the bioleaching technology for
projects related to environmental remediation of mine tailings.


CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Except for statements of historical fact relating to the Company, certain
information contained herein constitutes "forward-looking statements".
Forward-looking statements are frequently characterized by words such as "plan,"
"expect," "project," "intend," "believe," "anticipate" and other similar words,
or statements that certain events or conditions "may" or "will" occur. 


Forward-looking statements are based on the opinions and estimates of management
at the date the statements are made, and are subject to a variety of risks and
uncertainties and other factors that could cause actual events or results to
differ materially from those projected in the forward-looking statements. 


These factors include the inherent risks involved in the exploration and
development of mineral properties, the uncertainties involved in interpreting
drilling results and other ecological data, fluctuating metal prices, the
possibility of project cost overruns or unanticipated costs and expenses,
uncertainties relating to the availability and costs of financing needed in the
future and other factors described in the section entitled "Risks" in the
Company's Management Discussion and Analysis for the Year Ended December 31,
2008. Circumstances or management's estimates or opinions could change. The
reader is cautioned not to place undue reliance on forward-looking statements.


Shares outstanding 89,264,706

1 Year Bristol Gate Concentrate... Chart

1 Year Bristol Gate Concentrate... Chart

1 Month Bristol Gate Concentrate... Chart

1 Month Bristol Gate Concentrate... Chart

Your Recent History

Delayed Upgrade Clock